FRSW 117
Alternative Names: FRSW-117; PEG Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinLatest Information Update: 13 Mar 2024
At a glance
- Originator Jiangsu Gensciences
- Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Factor VIII replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Haemophilia A
Most Recent Events
- 27 Dec 2023 Phase-III clinical trials in Haemophilia A (In adolescents, Treatment-experienced, In adults) in China (Parenteral) (NCT06142552)
- 09 Dec 2023 Preliminary efficacy, adverse events, pharmacodynamics and pharmacokinetics data from a phase II trial in Haemophilia A presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 27 Nov 2023 Jiangsu Gensciences plans a phase III trial in Hemophilia A (In adolescents, In adults) in China [Parenteral,Injection] in November 2023 (NCT06142552)